Biochimie. 2026 Nov 14:S0300-9084(26)00295-6. doi: 10.1016/j.biochi.2026.11.003. Online ahead of print.
ABSTRACT
In the present study, a series of novel 9-N-n-alkyl derivatives of tetrahydroberberine was synthesized, and their hypoglycemic activity was screened using an OGTT. Based on the results, the most active compound (9-N-dodecyltetrahydroberberine) was selected for further investigation upon long-term administration in mice with genetically determined T2DM (Ay/a mice, AY) and STZ-induced T2DM. Administration of this compound at a dose of 30 mg/kg improved glucose tolerance in both AY mice and mice with STZ-induced T2DM, enhanced insulin sensitivity, and led to a significant reduction in body weight in AY mice. However, no effect of the studied compound on lipid metabolism and liver enzyme activity was observed in the experimental animals. To investigate the mechanism underlying the enhanced insulin sensitivity observed in vivo, we examined the interaction of the compound with the insulin receptor in vitro. Using NMR spectroscopy, we demonstrated that 9-N-dodecyltetrahydroberberine selectively interacts with the N-terminal part of the transmembrane domain of the insulin receptor (IR), presumably potentiating the receptor switching to an active conformation. Enhanced phosphorylation of IR after incubation with 9-N-dodecyltetrahydroberberine was also detected. Overall, these findings suggest that 9-N-dodecyltetrahydroberberine exerts its effects on glucose metabolism by specifically targeting IR, positioning this novel compound as a promising pharmacological agent for diabetes treatment.
PMID:43033962 | DOI:10.1016/j.biochi.2026.11.003

